Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
DF/CHCC specialists recommend genetic counseling for children with Li-Fraumeni syndrome

DF/CHCC specialists recommend genetic counseling for children with Li-Fraumeni syndrome

Study implicates 'arms race' between genes and germs

Study implicates 'arms race' between genes and germs

Researchers discover function and expression of CD97 in malignant gliomas

Researchers discover function and expression of CD97 in malignant gliomas

EpiCept seeks FDA Fast Track designation for AmiKet to treat CIPN

EpiCept seeks FDA Fast Track designation for AmiKet to treat CIPN

Researchers discover how SHP-2 genetic defect may result in heart malformation

Researchers discover how SHP-2 genetic defect may result in heart malformation

EntreMed receives $9.3 million in strategic financing

EntreMed receives $9.3 million in strategic financing

Tennessee Gov. declares February as 'St. Jude Month'

Tennessee Gov. declares February as 'St. Jude Month'

NCDB: Five-year survival rates higher among cancer patients treated in SCCA

NCDB: Five-year survival rates higher among cancer patients treated in SCCA

Immune cells from healthy individuals effectively kill cancer cells

Immune cells from healthy individuals effectively kill cancer cells

EUSA Pharma acquires ASPAREC development and commercialization rights

EUSA Pharma acquires ASPAREC development and commercialization rights

Novartis' Gleevec receives FDA approval for use in patients with CD117-positive GIST

Novartis' Gleevec receives FDA approval for use in patients with CD117-positive GIST

Study pinpoints genetic factors behind increased ALL risk in Hispanic children

Study pinpoints genetic factors behind increased ALL risk in Hispanic children

Newly discovered molecular pathway may explain how AML develops

Newly discovered molecular pathway may explain how AML develops

Researchers identify two genetic mutations responsible for brain cancer in children

Researchers identify two genetic mutations responsible for brain cancer in children

Cancer Research UK opens first AT9283 trial to treat childhood leukaemia

Cancer Research UK opens first AT9283 trial to treat childhood leukaemia

New links between leukemia cells and osteoblasts

New links between leukemia cells and osteoblasts

Amgen enters definitive merger agreement to acquire Micromet

Amgen enters definitive merger agreement to acquire Micromet

Celgene signs definitive merger agreement to acquire Avila

Celgene signs definitive merger agreement to acquire Avila

Mass. Gov. again seeks health insurance payment overhaul; Iowa lawmakers review denial of health coverage to residents with HIV

Mass. Gov. again seeks health insurance payment overhaul; Iowa lawmakers review denial of health coverage to residents with HIV

Chromosome aberrations happen in pairs when it comes to cancer

Chromosome aberrations happen in pairs when it comes to cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.